-
Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says
Thursday, December 13, 2018 - 5:30pm | 415Read More...Akebia Therapeutics Inc (NASDAQ: AKBA) announced shareholder approval this week for its merger with Keryx Biopharmaceuticals (NASDAQ: KERX). The Analyst Analyst Reni Benjamin of Raymond James maintains an Outperform rating on Akebia and raised the price target from $18 to $21. The Thesis The...
-
Analysts Remain Encouraged By Bellicum Pharma's Progress
Tuesday, June 27, 2017 - 3:07pm | 299Read More...Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) has managed to keep sell-side analysts encouraged with its last Friday's presentation at the European Hematology Association meeting. The latest sell-side firm to express its happiness over the data was Raymond James. Analyst Reni Benjamin termed the...
-
Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics
Friday, April 21, 2017 - 10:57am | 420Read More...Reni Benjamin of Raymond James maintains a Strong Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) after hosting an investor meeting with Charles Farber, a notable physician at the Summit Medical Group. Benjamin noted Farber's practice treats approximately 80 patients per week who suffer from...
-
Raymond James: Fate Therapeutics & Ocata Expected To Beat Market
Tuesday, October 6, 2015 - 10:25am | 529Read More...Fate Therapeutics Inc (NASDAQ: FATE) shares are down 5 percent since July 7, while shares of Ocata Therapeutics Inc (NASDAQ: OCAT) have lost 10 percent over the same period. Raymond James’ Reni Benjamin initiated coverage of both the companies with Outperform ratings and price targets...
-
3 Stocks That Made A Big Impact At ASCO
Wednesday, June 3, 2015 - 11:55am | 599Read More...The American Society of Clinical Oncology (ASCO) conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and pharmaceutical companies to share research and new best practices. H.C. Wainwright analyst Reni Benjamin attended several...
-
H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE
Thursday, April 2, 2015 - 10:27am | 148Read More...In a report published Thursday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $6.00 price target on OXiGENE Inc. (NASDAQ: OXGN). In the report, H.C. Wainwright & Co. noted, "We are reiterating our Buy rating and 12-month target price of $6 based on a discounted P/E...
-
Wainwright Sees TG Therapeutics As Take-Out Target
Monday, October 27, 2014 - 1:20pm | 223Read More...TG Therapeutics Inc's (NASDAQ: TGTX) increasingly attractive drug development pipeline could make it an acquisition target, an analyst said Monday. Pharmacyclics, Inc. (NASDAQ: PCYC) "represents the ideal suitor" for TG Therapeutics, according to H.C. Wainwright's Reni...
-
UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside
Monday, October 27, 2014 - 8:19am | 185Read More...In a report published Monday, H.C. Wainwright analyst Reni Benjamin initiated coverage on TG Therapeutics (NASDAQ: TGTX) with a Buy rating and $17.00 price target. In the report, H.C. Wainwright noted, “We are initiating coverage of TG Therapeutics with a Buy rating and a target price of $17, based...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside
Tuesday, October 21, 2014 - 9:20am | 182Read More...In a report published Tuesday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and $4.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Oncothyreon Inc. with a Buy rating and a 12-month...
-
H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals
Friday, August 8, 2014 - 9:31am | 155Read More...In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $15.00 price target on Spectrum Pharmaceuticals (NASDAQ: SPPI). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating for Spectrum Pharmaceuticals and a 12-month...
-
H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued
Friday, August 8, 2014 - 9:24am | 191Read More...In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $19.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating on Keryx Pharmaceuticals and maintaining our...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage on GenVec as Overlooked Key Innovator
Monday, February 24, 2014 - 9:54am | 186Read More...In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on GenVec (NASDAQ: GNVC) with a Buy rating and $9.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of GenVec with a BUY rating and a target price of $9. The...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody Acquisition
Monday, February 24, 2014 - 8:55am | 169Read More...In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Agenus (NASDAQ: AGEN) with a Buy rating and $8.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Agenus with a BUY rating and a target price of $8. In...
-
UPDATE: H.C. Wainwright Initiates Coverage on Spectrum Pharmaceuticals on EPS Valuation Methodology
Monday, October 7, 2013 - 11:30am | 182Read More...In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Spectrum Pharmaceuticals (NASDAQ: SPPI) with a Buy rating and $15.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Spectrum Pharmaceuticals with a BUY...
-
UPDATE: H.C. Wainwright Initiates Coverage on Keryx Biopharmaceuticals on Discounted Revenues, EPS Valuation Methodology
Wednesday, September 25, 2013 - 11:15am | 138Read More...In a report published Wednesday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Buy rating and $15.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Keryx Biopharmaceuticals with a...
